Banner
•••
Horizon 2020 (2014 - 2020)

Innovations to Accelerate Vaccine Development and Manufacture

Last update: May 13, 2022 Last update: 13 May, 2022

Details

Locations: Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Portugal, Sweden, Switzerland
Start Date: Sep 1, 2021
End Date: Feb 28, 2027
Value: 38 542 552 EUR
Sectors: Health, Research Health, Research
Categories: Grants
Date posted: May 13, 2022

Associated funding

Associated experts

Description

Programme(s): H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being; H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s): IMI2-2020-20-02 - Innovations to accelerate vaccine development vaccine development and manufacture

Call for proposal: H2020-JTI-IMI2-2020-20-two-stage

Funding Scheme: IMI2-RIA - Research and Innovation action

Grant agreement ID: 101007799

Objective: Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling persistent scientific bottlenecks in vaccine development and for de-risking and accelerating this process. To reach this aim the project is divided into four interlinked subtopics. In Subtopic 1, artificial intelligence in combination with big data analysis and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Subtopic 2 will develop new and improved controlled human infection models (CHIM) against influenza, RSV and C. difficile that will enable early vaccine efficacy evaluation. Subtopic 3 will contribute to the development of cell-based human in vitro 3D models that resemble the in vivo situation of an infection at the mucosa and more reliably predict immune protection. These models will be combined with the development of related functional immune assays for clinically relevant (surrogate) endpoints. Finally, Subtopic 4 will develop a modular one-stop computational platform for in silico modelling of vaccine biomanufacturing and stability testing. In parallel to the scientific-technical work, the partners will develop strategies and roadmaps for positioning the newly developed models in the regulatory framework and integrating them into pharmaceutical vaccine development. The overall workplan is underpinned by horizontal activities on coordination/management and dissemination/communication, including data management and future sustainability. To achieve these ambitious objectives, Inno4Vacc has assembled a multidisciplinary consortium from academic and research institutions, industries, regulatory bodies, and vaccine R&D alliances. This unique partnership brings together clinical, immunological, microbiological, systems biology, mathematical models, and regulatory expertise and includes world-leaders in each respective field.

Reference — Innovations to Accelerate Vaccine Development and Manufacture — for Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Portugal, Sweden, Switzerland presented by Horizon 2020 (2014 - 2020) (grants), budget is 38 542 552 EUR, in Health, Research sectors. Reference — Innovations to Accelerate Vaccine Development and Manufacture — for Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Portugal, Sweden, Switzerland presented by Horizon 2020 (2014 - 2020) (grants), budget is 38 542 552 EUR, in Health, Research sectors. Reference — Innovations to Accelerate Vaccine Development and Manufacture — for Belgium, Denma...
Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.